Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans

Pharmacogenetics

Volumn 9, Issue 4, 1999, Pages 435-443

  Lessard, Étienne ^c   Yessine, Marie Andrée ^c   Hamelin, Bettina A ^c   O'Hara, Gilles ^c   LeBlanc, Jacynthe ^a   Turgeon, Jacques ^b  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c NONE

Author keywords

CYP2D6; Cytochrome P 450; Metabolism; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; QUINIDINE; VENLAFAXINE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART PALPITATION; HEREDITY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; METHYLATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREMOR;

EID: 0032847231     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Amchin J, Zarycranski W, Taylor K. Evidence that venlafaxine does not inhibit CYP1A2 as measured in vivo by the metabolism of caffeine (abstract). Clin Pharmacol Ther 1997; 61:179.
2. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharm Bull 1998a; 34:211-219.
3. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of terfenadine. Psychopharm Bull 1998b; 34:383-389.
4. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.
5. Breimer DD. Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet 1983; 12:779-784.
6. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Phamacokinet Biopharmaceut 1978; 6:539-546.
7. Dayer P, Kronbach T, Eichelbaum M, Meyer UA. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 1987; 36:4145-4152.
8. East T, Dye D. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1985; 338:99-112.
9. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16 (Suppl. 2):37S-53S.
10. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 1994a; 350:434-439.
11. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994b; 4:271-274.
12. Fabre LF, Putman HP. An ascending single-dose tolerance study of Wy-45.030 a bicyclic antidepressant in healthy men. Curr Ther Res 1987; 42:901-909.
13. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154:1760-1762.
14. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: influence of genetic polymorphism. J Pharmacol Exp Ther 1989; 249:134-142.
15. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
16. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49:280-294.
17. Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991; 49:410-419.
18. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23:349-359.
19. Khalifa M, Drolet B, Hamelin BA, Turgeon J. Modulation of cardiac repolarization by venlafaxine. XIXth Congress of the European Society of Cardiology (abstract). Eur Heart J 1997; 18:88.
20. Khalifa M, Daleau P, Drolet B, Turgeon J. Block of sodium channels underlies unheralded cardiac toxicity observed with the antidepressant agent venlafaxine. World Congress of the International Society of Heart Research (abstract). J Mol Cell Cardiol 1998; 30:A136.
21. Klamerus KJ. Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active-O-desmethyl metabolite. J Clin Pharmacol 1992; 32:716-724.
22. Kokan L, Dart RC. Life-threatening hypotension from venlafaxine overdose (abstract). Ann Emerg Med 1996; 27:815.
23. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45:030, an ethyl cyclohexanol derivative. Drug Dev Res 1991; 23:191-193.
24. Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Harwick JP, Inaba T, Kalow W. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990; 276:424-432.
25. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41:149-156.
26. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984; 34:73-80.
27. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 (Suppl. 1):24-32.
28. Patat A, Troy S, Burke J, Trocherie S, Danjou P, Le Coz F, et al. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. J Clin Pharmacol 1998; 38:256-267.
29. Peano C, Leikin JB, Hanashiro PK. Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine. Ann Emerg Med 1997; 30:704-708.
30. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75:785-791.
31. Sisenwine SF, Politowski J, Birk K, White G, Dyroff M. A prefatory investigation of the metabolic disposition of Wy-45.030 in man (abstract). Acta Pharmacol Toxicol 1986; 59 (Suppl. 5): 312.
32. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-261.
33. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5:215-223.
34. Troy SM, Rudolph R, Mayersohn M, Chiang ST. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol 1998; 38:467-474.
35. Vu RL, Helmeste D, Albers L, Reist C. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatog B 1997; 703:195-201.
36. Wang CP, Howell SR, Scantina J, Sisenwine SF. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992; 4:84-90.
37. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51:165-172.